The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Childhood maltreatment is associated with a poor treatment response to conventional antidepressants and increased risk for treatment-resistant depression (TRD). The N-methyl-D-aspartate receptor (NDMAR) antagonist ketamine has been shown to rapidly improve symptoms of depression in patients with TRD. It is unknown if childhood maltreatment could influence ketamine’s treatment response. We examined the relationship between childhood maltreatment using the Childhood Trauma Questionnaire (CTQ) and treatment response using the Quick Inventory of Depressive Symptoms–Self Report (QIDS-SR) in TRD patients receiving intravenous ketamine at a community outpatient clinic. We evaluated treatment response after a single infusion (n = 115) and a course of repeated infusions (n = 63). Repeated measures general linear models and Bayes factor (BF) showed significant decreases in QIDS-SR after the first and second infusions, which plateaued after the third infusion. Clinically significant childhood sexual abuse, physical abuse, and cumulative clinically significant maltreatment on multiple domains (maltreatment load) were associated with better treatment response to a single and repeated infusions. After repeated infusions, higher load was also associated with a higher remission rate. In contrast to conventional antidepressants, ketamine could be more effective in TRD patients with more childhood trauma burden, perhaps due to ketamine’s proposed ability to block trauma-associated behavioral sensitization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, prelimi nary evidence suggests that response to vortioxetine or ketamine treatment in depression is not reduced in persons with trauma, suggesting different outcomes as a function of the putative mechanism of action of medi cations 126,127 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [127]
The cited source says what the claim attributes to it.
In the citing paper
“The attenuated response to antidepressants in persons with a history of childhood maltreatment may not, however, occur with all antidepressants.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Initial reliability and validity of a new retrospective measure of child abuse and neglect
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1132 · Cited by 3,577 · cited 3×
“The CTQ [41,42] is a 28-item self-report scale measuring childhood maltreatment prior to the age of 18.”
MethodBardo, M. T., & Hammer, R. P. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90226-e · Cited by 3,219
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947 · cited 3×
“2% of US residents 13 years and older have a lifetime history of recurring major depressive episodes associated with major depressive disorder (MDD) or bipolar disorder (BD) [1].”
BackgroundInfluentialKalivas, P. W., & Stewart, J. (1991) · Brain Research Reviews · doi:10.1016/0165-0173(91)90007-u · Cited by 2,019
Bayesian inference for psychology. Part II: Example applications with JASP
Wagenmakers, E.-J., Love, J., Marsman, M., Jamil, T., Ly, A., Verhagen, J., Selker, R., Gronau, Q. F., Dropmann, D., Boutin, B., et al. (2018) · Psychonomic Bulletin & Review · doi:10.3758/s13423-017-1323-7 · Cited by 1,715
Nanni, V., Uher, R., & Danese, A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020335 · Cited by 1,480 · cited 2×
“A history of childhood maltreatment has been associated with a diminished treatment response to conventional antidepressant treatments [17].”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“Weight based dosing of IV ketamine was delivered over 40 min–2 h as per standard procedures described in numerous publications [6,43].”
MethodSelf-citationBaldwin, J. R., Reuben, A., Newbury, J. B., & Danese, A. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0097 · Cited by 1,094 · cited 1×
“It is also a retrospective measure, which may be affected by recall bias, with patients either minimizing or exaggerating actual maltreatment [40].”
Background
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Teicher, M. H., Gordon, J. B., & Nemeroff, C. B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01367-9 · Cited by 325
“[33] recently reported that participants with refractory depression and CM had a substantially better response to intravenous ketamine than refractory depressed individuals without CM.”
BackgroundGáll, Z., Farkas, S., Albert, Á., Ferencz, E., Vancea, S., Urkon, M., & Kolcsár, M. (2020) · Biomolecules · doi:10.3390/biom10050801 · Cited by 101
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Jollant, F., Colle, R., Nguyen, T. M. L., Corruble, E., Gardier, A. M., Walter, M., Abbar, M., & Wagner, G. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231151327 · Cited by 56
Ketamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Kritzer, M. D., Mischel, N., Young, J. R., Lai, C. S., Masand, P. S., Szabo, S. T., & Mathew, S. J. (2021) · Annals of Clinical Psychiatry · doi:10.12788/acp.0048 · Cited by 45
Self-citationPersonalized use of ketamine and esketamine for treatment-resistant depression
Medeiros, G. C., Demo, I., Goes, F. S., Zarate, C. A., & Gould, T. D. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03180-8 · Cited by 51
“…with a more robust response to ketamine including higher body mass index [87, 89], positive history of clinically signi fi cant childhood trauma [90, 91], positive personal history of AUD [88], greater anhedonia scores [78], presence of anxious features [81], and absence of melancholic features…”
SAMSON, J. A., Newkirk, T., & Teicher, M. H. (2023) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13883 · Cited by 50
Georgiou, P., Farmer, C., Medeiros, G. C., Yuan, P., Johnston, J. N., Kadriu, B., Gould, T. D., & Zarate, C. A. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.12.036 · Cited by 38
Cytokine and Reward Circuitry Relationships in Treatment-Resistant Depression
Rengasamy, M. L., Brundin, L., Griffo, A., Panny, B., Capan, C. D., Forton, C., & Price, R. B. (2021) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.06.009 · Cited by 30
“50%) report a history of childhood trauma (25,26), which contributes to overall refractory outcomes in depression (27,28).”
BackgroundTranscriptional signatures of early-life stress and antidepressant treatment efficacy
Parel, S. T., Bennett, S. N., Cheng, C., Timmermans, O. C., Fiori, L. M., Turecki, G., & Peña, C. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305776120 · Cited by 26
“Interestingly, some research has suggested that depressed patients with a history of ELS may achieve a more efficacious response to subanesthetic ketamine treatment—increasingly used as a rapid-acting antidepressant—compared to traditional monoamine-targeting antidepressants (10).”
BackgroundResultKetamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Psychological Aspects of Child Maltreatment
Ahn, Y. D., Jang, S., Shin, J., & Kim, J.-W. (2022) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2021.0300 · Cited by 22
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.003 · Cited by 18
Constantino, J. L., Godschalk, M., van Dalfsen, J. H., Veraart, J. K. E., Spijker, J., van Exel, E. R., Schoevers, R. A., & Kamphuis, J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116355 · Cited by 23
“Childhood sexual abuse ( N = 182) (O ’ Brien et al., 2019; Magalhaes et al., 2021) was investigated in two studies, with one study ( N = 67) reporting no association (Magalhaes et al., 2021) and another study ( N = 115) a positive association (O ’ Brien et al., 2019) with response.”
Distinct trajectories of antidepressant response to intravenous ketamine
O’Brien, B., Lijffijt, M., Lee, J., Kim, Y. S., Wells, A. A., Murphy, N., Ramakrishnan, N., Swann, A. C., & Mathew, S. J. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.006 · Cited by 25
“321 patients have suboptimal responses to ketamine, thus making it important to evaluate predictors of treatment outcomes (O’Brien et al., 2019; Rong et al., 2018).”
InfluentialSelf-citationKetamine for Treatment of Posttraumatic Stress Disorder: State of the Field
Fremont, R., Brown, O., Feder, A., & Murrough, J. W. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20230006 · Cited by 18
Replication of distinct trajectories of antidepressant response to intravenous ketamine
O’Brien, B., Lee, J., Kim, S., Nandra, G. S., Pannu, P., Swann, A. C., Murphy, N., Tamman, A. J. F., Amarneh, D. Y., Lijffijt, M., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.10.031 · Cited by 15
Self-citationVeraart, J. K. E., Kamphuis, J., Schlegel, M., & Schoevers, R. A. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-238135 · Cited by 13
The why, when, where, how, and so what of so-called rapidly acting antidepressants
Schatzberg, A. F., & Mathew, S. J. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01647-8 · Cited by 11
“Accordingly, many ketamine treatment centers have adopted a twice weekly infusion schedule for the initial acute induction period [49, 50], and this schedule is recommended for esketamine nasal spray during the induction period (see below).”
BackgroundSelf-citationBridging early life trauma to difficult-to-treat depression: scoping review
Paganin, W., Signorini, S. G., & Sciarretta, A. (2024) · BJPsych Bulletin · doi:10.1192/bjb.2024.75 · Cited by 7
“O ’ Brien et al 59,66,71 suggested that ketamine may be e ff ective for ELT patients with TRD, particularly those with histories of childhood abuse.”
Early or recent trauma in treatment-resistant depression: a systematic review
Fantasia, S., Conti, L., Andreoli, D., Bordacchini, A., Rimoldi, B., Dell’Oste, V., Pedrinelli, V., & Carmassi, C. (2025) · CNS Spectrums · doi:10.1017/s1092852925000185 · Cited by 10
“O ’ Brien et al. 42 also concluded that ketamine may be more effective in TRD patients with higher childhood trauma burden.”
Nonresponse to Ketamine in Treatment‐Resistant Bipolar Depression
Kachlik, Z., Cubała, W. J., Walaszek, M., Pastuszak, M., Pastuszak, K., & Kwaśny, A. (2025) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70038 · Cited by 6
“…given that certain comorbidities—such as SUD, especially alcohol use disorder [18], anxious distress [7, 19, 20], borderline personality disorder [21], and trauma, particularly childhood maltreatment [22]—have, in some studies, been associated with potential therapeutic benefits of ketamine.”
van Oort, J., Tendolkar, I., Vrijsen, J. N., Collard, R. M., Gardner, G., Duyser, F. A., Fernández, G., Bachi, K., & van Eijndhoven, P. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.03.194 · Cited by 5
Blevins, E. J., Slopen, N. B., Koenen, K. C., Mikesell, C., & Basu, A. (2024) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000413 · Cited by 4
Johnson, D. E., Rodrigues, N. B., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13812 · Cited by 5
“However, our results contrast with the earliest study by O'Brien et al. [27], which reported that patients with significant childhood sexual abuse, physical abuse, and cumulative maltreatment load responded better to both single ( n = 115) and repeated ( n = 63) ketamine infusions than patients…”
InfluentialQu, M., Wang, D., Tian, Y., Chen, J., Zhu, R., Li, Y., & Zhang, X. (2023) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-023-01209-5 · Cited by 3
“On the one hand, low social support is associated with high depressive symptoms, and on the other hand, low levels of social support may be associated with reduced effectiveness of subsequent treatment processes (O’Brien et al., 2019).”
Psychedelics - A Cure for Sexual Trauma or a Risk Factor in Recreational and Treatment Settings?
Struble, C. A. (2025) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-025-00372-x · Cited by 2
Peters, E. M., Halpape, K., Cheveldae, I., Jacobson, P., & Wanson, A. (2024) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2024.100119 · Cited by 7
Syed, O. A., Sobolenko, V., Nestor, S. M., Husain, M. I., Lipsman, N., Alam, F., & Giacobbe, P. (2026) · CNS Drugs · doi:10.1007/s40263-026-01296-7 · Cited by 2
“Overall, two studies found childhood maltreatment and adverse childhood events to be a positive predictor [58, 132].”
Influential2019: An Awesome Year for Pharmaceuticals
Eynde, J. J. V. (2020) · Pharmaceuticals · doi:10.3390/ph13010006 · Cited by 1
Behavioural and molecular effects induced by Cannabidiol in animal models of depression
Silote, G. P. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.60.2021.tde-29092021-060118
Grundlagen der Diagnostik und Therapie
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-22487-4.16001-0
Kosted, R., Waddell, A., Adolph, K., & Fonzo, G. A. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121350 · Cited by 1
Metadata
- Authors
- O’Brien, B., Lijffijt, M., Wells, A., Swann, A. C., & Mathew, S. J.
- Affiliations
- Michael E. DeBakey VA Medical Center (US)
- Lone Star Infusion, PLLC, Houston, TX 77079, USA
- Corresponding author
- O’Brien, Brittany
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-09-11
- Volume
- 12
- Issue
- 3
- Pages
- 133
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789614
- OpenAlex
- W2972990098
- Cited by
- 33
- References
- 47
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 3 · 2021: 6 · 2020: 3
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- child abuse, treatment-resistant depression, intravenous ketamine, child sexual abuse, physical abuse, remission, NMDA receptor antagonists, antidepressant response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.